ATE391493T1 - Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung - Google Patents

Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung

Info

Publication number: ATE391493T1
Authority: AT; Austria
Prior art keywords: tobramycin; loteprednol etabonate; suspension; topical ophthalmic; ophthalmic use
Prior art date: 2003-10-31

Application number

AT04810041T

Other languages

English (en)

Inventor

Ramesh Krishnamoorthy

Original Assignee

Bausch & Lomb

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-31

Filing date

2004-10-27

Publication date

2008-04-15

2004-10-27 Application filed by Bausch & Lomb filed Critical Bausch & Lomb

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE391493T1 publication Critical patent/ATE391493T1/de

Links

229960003744 loteprednol etabonate Drugs 0.000 title abstract 2
229960000707 tobramycin Drugs 0.000 title abstract 2
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 title abstract 2
230000000699 topical effect Effects 0.000 title abstract 2
DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 title 1
239000000725 suspension Substances 0.000 title 1
238000009472 formulation Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
206010061218 Inflammation Diseases 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1
-1 steroid loteprednol etabonate Chemical class 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT04810041T 2003-10-31 2004-10-27 Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung ATE391493T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/698,322 US20050095205A1 (en)	2003-10-31	2003-10-31	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use

Publications (1)

Publication Number	Publication Date
ATE391493T1 true ATE391493T1 (de)	2008-04-15

Family

ID=34550614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04810041T ATE391493T1 (de)	2003-10-31	2004-10-27	Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung

Country Status (13)

Country	Link
US (2)	US20050095205A1 (de)
EP (1)	EP1677761B1 (de)
JP (2)	JP2007509952A (de)
KR (1)	KR101086990B1 (de)
CN (1)	CN1897917A (de)
AT (1)	ATE391493T1 (de)
AU (1)	AU2004287443B2 (de)
BR (1)	BRPI0416123B8 (de)
CA (1)	CA2544139C (de)
DE (1)	DE602004013035T2 (de)
ES (1)	ES2303967T3 (de)
TW (1)	TWI359022B (de)
WO (1)	WO2005044231A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050197303A1 (en) *	2003-10-31	2005-09-08	Bausch & Lomb Incorporated	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050095205A1 (en) *	2003-10-31	2005-05-05	Ramesh Krishnamoorthy	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
WO2007032997A1 (en) *	2005-09-13	2007-03-22	Bausch & Lomb Incorporated	Ophthalmic formulation containing loteprednol etabonate for treatment of dry eye
US20070093461A1 (en) *	2005-10-26	2007-04-26	Bausch & Lomb Incorporated	Effect of Loteprednol etabonate on vascular dysfunction
US7767217B2 (en) *	2006-03-14	2010-08-03	Foresight Biotherapeutics	Ophthalmic compositions comprising povidone-iodine
CN101410123A (zh) *	2006-03-28	2009-04-15	杰佛林制药公司	低剂量的双氯芬酸和β－环糊精的制剂
US20070232567A1 (en) *	2006-03-28	2007-10-04	Curtis Wright	Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
WO2008085913A1 (en) *	2007-01-04	2008-07-17	Rib-X Pharmaceuticals, Inc.	Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
CN101317847B (zh) *	2007-06-06	2010-10-13	深圳市瑞谷医药技术有限公司	一种眼用或耳鼻用药物组合物及其用途
US20090239836A1 (en) *	2008-03-24	2009-09-24	Mary Lee Ciolkowski	Multifunctional Ophthalmic Compositions
CN105944105A (zh) *	2008-06-12	2016-09-21	前瞻生物治疗公司	一种眼科组合物中的防腐剂替代物聚维酮碘
US20120135947A1 (en) *	2010-11-29	2012-05-31	Mitsubishi Tanabe Pharma Corporation	Oil-in-water emulsion composition containing difluprednate and tobramycin
WO2013065029A1 (en) *	2011-11-04	2013-05-10	Micro Labs Limited	Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja)	2012-05-03	2018-07-18	カラファーマシューティカルズインコーポレイテッド	複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
ES3055223T3 (en)	2012-05-03	2026-02-10	Alcon Inc	Pharmaceutical nanoparticles showing improved mucosal transport
US20190160003A1 (en) *	2016-05-05	2019-05-30	Veloce Biopharma, Llc	Compositions and methods for treatment of inflammation or infection of the eye
WO2018212846A1 (en) *	2017-05-19	2018-11-22	Ocugen, Inc.	Ophthalmic compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6610675B1 (en) *	1980-07-10	2003-08-26	Nicholas S. Bodor	Inactive metabolite approach to soft drug design
US4710495A (en) *	1980-07-10	1987-12-01	Otsuka Pharmaceutical Co., Ltd.	Soft steroids having anti-inflammatory activity
US4996335A (en) *	1980-07-10	1991-02-26	Nicholas S. Bodor	Soft steroids having anti-inflammatory activity
US5192535A (en) *	1988-02-08	1993-03-09	Insite Vision Incorporated	Ophthalmic suspensions
US5149693A (en) *	1988-03-09	1992-09-22	Alcon Laboratories, Inc.	Combination of tobramycin and fluorometholone for topical ophthalmic use
US5340572A (en) *	1993-02-08	1994-08-23	Insite Vision Incorporated	Alkaline ophthalmic suspensions
US5540930A (en) *	1993-10-25	1996-07-30	Pharmos Corporation	Suspension of loteprednol etabonate for ear, eye, or nose treatment
TW503113B (en) *	1997-01-16	2002-09-21	Senju Pharma Co	Aqueous suspension for nasal administration
KR100508227B1 (ko) *	1997-03-14	2006-03-23	센주 세이야꾸 가부시키가이샤	로테프레드놀에타보네이트수성현탁액
JP3147076B2 (ja) *	1997-03-14	2001-03-19	千寿製薬株式会社	ロテプレドノールエタボネート水性懸濁液
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US20010049366A1 (en) *	2000-02-09	2001-12-06	Alcon Universal Ltd.	Topical solution formulations containing an antibiotic and a corticosteroid
US20020098154A1 (en) *	2001-01-20	2002-07-25	Dyer Gordon Wayne	Methods and apparatus for medicating the nasal sinuses
WO2005000317A1 (en) *	2003-06-19	2005-01-06	Bodor Nicholas S	Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application
US20050095205A1 (en) *	2003-10-31	2005-05-05	Ramesh Krishnamoorthy	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use

2003
- 2003-10-31 US US10/698,322 patent/US20050095205A1/en not_active Abandoned
2004
- 2004-10-27 EP EP04810041A patent/EP1677761B1/de not_active Expired - Lifetime
- 2004-10-27 ES ES04810041T patent/ES2303967T3/es not_active Expired - Lifetime
- 2004-10-27 WO PCT/US2004/035562 patent/WO2005044231A1/en not_active Ceased
- 2004-10-27 CA CA2544139A patent/CA2544139C/en not_active Expired - Fee Related
- 2004-10-27 BR BRPI0416123A patent/BRPI0416123B8/pt not_active IP Right Cessation
- 2004-10-27 CN CNA2004800382496A patent/CN1897917A/zh active Pending
- 2004-10-27 AT AT04810041T patent/ATE391493T1/de active
- 2004-10-27 KR KR1020067010559A patent/KR101086990B1/ko not_active Expired - Fee Related
- 2004-10-27 AU AU2004287443A patent/AU2004287443B2/en not_active Ceased
- 2004-10-27 DE DE602004013035T patent/DE602004013035T2/de not_active Expired - Lifetime
- 2004-10-27 JP JP2006538199A patent/JP2007509952A/ja not_active Withdrawn
- 2004-10-28 TW TW093132835A patent/TWI359022B/zh not_active IP Right Cessation
2009
- 2009-09-01 US US12/584,186 patent/US20100003334A1/en not_active Abandoned
2012
- 2012-02-02 JP JP2012020684A patent/JP5726774B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HK1092354A1 (en)	2007-02-09
KR20060110312A (ko)	2006-10-24
US20050095205A1 (en)	2005-05-05
AU2004287443A1 (en)	2005-05-19
JP2012087151A (ja)	2012-05-10
DE602004013035T2 (de)	2009-05-07
CN1897917A (zh)	2007-01-17
WO2005044231A1 (en)	2005-05-19
US20100003334A1 (en)	2010-01-07
TWI359022B (en)	2012-03-01
AU2004287443B2 (en)	2011-01-27
EP1677761B1 (de)	2008-04-09
ES2303967T3 (es)	2008-09-01
EP1677761A1 (de)	2006-07-12
KR101086990B1 (ko)	2011-11-29
JP2007509952A (ja)	2007-04-19
TW200526235A (en)	2005-08-16
CA2544139C (en)	2012-10-09
BRPI0416123B1 (pt)	2018-11-21
CA2544139A1 (en)	2005-05-19
JP5726774B2 (ja)	2015-06-03
BRPI0416123A (pt)	2007-01-02
DE602004013035D1 (de)	2008-05-21
BRPI0416123B8 (pt)	2021-05-25

Legal Events

Date

Code

Title

Description

2008-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1677761

Country of ref document: EP

Publication	Publication Date	Title
ATE391493T1 (de)	2008-04-15	Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung
HK1038693A1 (zh)	2002-03-28	治疗眼、耳、鼻病症的抗生素合成剂
DE50312034D1 (de)	2009-11-26	Liposomale glucocorticoide
BRPI0410503A (pt)	2006-06-20	uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
WO2001089496A3 (en)	2002-04-25	Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics
WO2005096990A3 (en)	2007-02-08	Novel modification of medical prostheses
BR0211062A (pt)	2004-07-20	Combinações para o tratamento de distúrbios inflamatórios
WO2004037201A3 (en)	2004-10-21	Topical skin care composition
RU2010123052A (ru)	2011-12-20	Авенантрамидсодержащие композиции
DE60138549D1 (de)	2009-06-10	Topische gel-abgabesysteme zur behandlung von hauterkrankungen
PT2336184E (pt)	2015-03-09	Administração de agentes para o tratamento da inflamação
DE60233212D1 (de)	2009-09-17	Immunstimulierende beschichtung für chirurgische vorrichtungen
BR0208533A (pt)	2004-04-20	Derivados de sapogenina, sìntese e uso dos mesmos e processos com base em seu uso
AR025923A1 (es)	2002-12-18	Nueva combinacion de loteprednol y antihistaminicos
WO2000018387A3 (en)	2000-07-06	Antibiotic compositions for treatment of the eye, ear and nose
DE60104194D1 (de)	2004-08-12	Kombination der progesteron und mifepristone für krebs-therapie
DK1343472T3 (da)	2006-09-25	Thixotropisk næsespray
UY29779A1 (es)	2006-12-29	Nitrooxi derivados de esteroides
DE60320034D1 (de)	2008-05-08	Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
ATE310539T1 (de)	2005-12-15	Artikel zur wundbehandlung
CY1106155T1 (el)	2011-06-08	Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
WO2001089495A3 (en)	2002-05-30	Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
WO2023212179A3 (en)	2024-01-18	Therapeutic compositions for skin disorders and wound repair
ATE427122T1 (de)	2009-04-15	Behandlung von dermatitis mit dehydroepiandrosteron-glucocorticoid- kombinationen
HUP0204180A2 (hu)	2003-04-28	Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére